Hints and tips:
Related Special Reports
...Joseph Dupont, then a vice-president at Alexion Pharmaceuticals, now owned by AstraZeneca, shared knowledge of an upcoming acquisition of Portola Pharmaceuticals with Shawn Cronin, a childhood friend and...
...The US drugmaker has spent almost $30bn on acquisitions over the past two years, snapping up Arena Pharmaceuticals, Biohaven Pharmaceuticals, Global Blood Therapeutics, ReViral and Trillium Therapeutics....
...Rivals AstraZeneca, Johnson & Johnson, Russia’s Sputnik V and new entrants such as Novavax make up the remainder of the market, which is forecast to double in value to $124bn next year....
...“Africa is a key market for Sputnik V,” said the Russian Direct Investment Fund, a Kremlin-run wealth fund overseeing Sputnik V’s foreign sales....
...After such strong reads from the first two releases (three if we count Russia’s Sputnik V), the disappointing AZN figures were perhaps bound to prompt downward pressure on the company’s shares....
...In August, Russia became the first country to approve a Covid-19 vaccine — named Sputnik V — for civilian use, but western experts cast doubt on its efficacy and safety....
...If there is a sense from this earnings season that confidence in a V-shaped recovery for profits is misplaced, then the impact will probably be hardest on companies with weak balance sheets, and on those...
...Beyond these three biotechs, Crispr could end up transforming the entire pharmaceutical industry....
...Their concentrated ownership of industries such as airlines and pharmaceuticals may push up travel and drug prices, some academics argue....
...Virgin Louis V on my back, baby. Living fast, dying slow, that's the catch, baby. Suicide doors, [MUTED] around and crash, baby. I do the dash, baby....
...She worked as a janitorial supervisor at C&W client Lonza, a Swiss pharmaceuticals group, which has a production facility in Portsmouth, New Hampshire....
...Investors say Pfizer is in much better shape than when he took the top job in 2010, shortly after the company had completed the ill-fated acquisition of Wyeth for $68bn....
...He places human embryonic and pluripotent stem cells — that have the potential to grow into nearly every cell of the body — in tiny ‘U’ or ‘V’ shaped dishes in the lab to grow them into different types of...
...The current version, mostly acquired with Wyeth in 2009, includes brands such as Centrum supplements and ChapStick....
...Pharmaceutical groups, which might see similar benefits from quantum technology in the long term, are still on the sidelines....
...But it subsequently took on a new portfolio when it acquired Wyeth in 2010....
...Thanks to a series of court rulings since the mid-2000s, such as eBay v MercExchange in 2007, Mayo Collaborative Services v Prometheus Laboratories in 2012 and Alice Corp v CLS Bank in 2014, and the subsequent...
...the neuroscience business should not “shock investors but is likely to raise a debate over possible use of proceeds should any cash be generated and management of any earnings dilution [ie deleveraging v...
...A 2009 Supreme Court case involving prescription drug labels, Wyeth v Levine, greenlighted state laws that are stricter than federal laws....
...(The Atlantic) Man v machine Sensitivity to “gut feelings” is a strong predictor of success in financial trading, according to research led by Cambridge university....
...A Louisiana doctor who has brought a series of whistleblower lawsuits against pharmaceuticals companies is in line for a windfall from Pfizer that would take his total payout from fraud settlements close...
...Hikma, the Jordan-founded but UK-listed drug maker, suffered a chunky drop in pre-tax profit in 2015, due in large part to a sharp decline in its generics business, where sales of a key gout medicine have...
...Ms Reid specialises in patent law in the pharmaceutical industry. She draws on her scientific background to create intellectual property strategies that benefit biotech and pharmaceutical start-ups....
...Martoma had obtained non-public information about an experimental drug for Alzheimer’s that was being developed by listed companies Elan and Wyeth....
...Shareholders are taking a dim view of the gloomier assessment by Hikma Pharmaceutical of Roxane Laboratories, which it agreed to buy last year....
International Edition